PEOPLE - Merck KGaA makes management changes:
This article was originally published in Clinica
Executive Summary
Merck KGaA (Germany) has made some senior management changes. Dr Jan Sombroeck becomes a board member, succeeding Klaus Gruber, who is due to retire at the end of June. Dr Sombroeck becomes head of Merck's preclinical R&D Pharma. Dr Inge Lues is promoted to vice-president, heading preclinical R&D pharma. She is currently responsible for Merck's biomedical research.